Partillion lands 10th SBIR grant, taking federal funding past $8M
What's the deal? Partillion BioscienceDealroom has a profile for this one. Try Dealroom → has secured a two-year, $2.1 million Small Business Innovation Research grant from the National Institute of General Medical SciencesDealroom has a profile for this one. Try Dealroom →, part of the National Institutes of HealthDealroom has a profile for this one. Try Dealroom →. The award funds the Los Angeles company's Cell-Cell-seq workflows, which analyse how cells interact.
By the numbers: It is Partillion's 10th SBIR grant, bringing total non-dilutive federal funding past $8 million — roughly matching private investment to date, with no equity exchanged. The $2.1 million round ranks in the 77th percentile by size among comparable deals.
What's the endgame? Most single-cell sequencing profiles cells in isolation, limiting study of how interactions shape disease and treatment response. Partillion's Nanovial technology, protected by 17 issued patents, preserves defined cell pairs and links functional outputs such as secretion, activation, and killing to sequencing data. The grant will scale Cell-Cell-seq toward datasets of up to one million cell pairs.
Why now? The award, made through NIH's Direct-to-Phase II mechanism, will also broaden compatibility with more sequencing platforms and fund new analysis tools.
What they're saying: "This award is meaningful because it reflects the scientific merit of Cell-Cell-seq and gives us the resources to move the platform forward," said Joseph de Rutte, co-founder and chief executive officer. It lets the company "pursue ambitious scientific work while keeping our private capital focused on customer adoption and commercial expansion," he added.
The context: Partillion launched a distribution partnership with Sony BiotechnologyDealroom has a profile for this one. Try Dealroom → in 2024. Its Nanovial platform also featured in a research collaboration with UCLA, USC, and Caltech, backed by the Chan Zuckerberg InitiativeDealroom has a profile for this one. Try Dealroom →.
The signal: By leaning on federal grants for research and development, Partillion is stretching its private capital toward commercial growth — a funding split that lets early-stage biotech advance ambitious science without diluting founders.
Read more: finance.yahoo.com
Image credit: Partillion Bioscience
